# NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment

> **NCT02239003** · PHASE2 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 24 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** DAOIB
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02239003
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239003, "NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02239003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*